Skip to main content
Kent Academic Repository

Efficacy of vasopressin, steroid, and epinephrine protocol for in-hospital cardiac arrest resuscitation: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis

Satti, Danish Iltaf, Lee, Yan Hiu Athena, Leung, Keith Sai Kit, Hui, Jeremy Man Ho, Kot, Thompson, Babar, Arslan, Mahalwar, Gauranga, Wai, Abraham Ka Chung, Liu, Tong, Roever, Leonardo, and others. (2022) Efficacy of vasopressin, steroid, and epinephrine protocol for in-hospital cardiac arrest resuscitation: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Journal of Geriatric Cardiology, 19 (9). pp. 705-711. ISSN 1671-5411. (doi:10.11909/j.issn.1671-5411.2022.09.002) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:99777)

The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided. (Contact us about this Publication)
Official URL:
http://dx.doi.org/10.11909/j.issn.1671-5411.2022.0...

Abstract

OBJECTIVES  To assess the effect of vasopressin, steroid and epinephrine (VSE) combination therapy on return of spontaneous circulation (ROSC) after in-hospital cardiac arrest (IHCA), and test the conclusiveness of evidence using trial sequential analysis (TSA).

METHODS  The systematic search included PubMed, EMBASE, Scopus, and Cochrane Central Register of Controlled Trials. Randomized controlled trials (RCTs) that included adult patients with IHCA, with at least one group receiving combined VSE therapy were selected. Data was extracted independently by two reviewers. The main outcome of interest was ROSC. Other outcomes included survival to hospital discharge or survival to 30 and 90 days, with good neurological outcomes.

RESULTS  We included a total of three RCTs (n = 869). Results showed that VSE combination therapy increased ROSC (risk ratio = 1.41; 95% CI: 1.25-1.59) as compared to placebo. TSA demonstrated that the existing evidence is conclusive. This was also validated by the alpha-spending adjusted relative risk (1.32 [1.16, 1.49], P < 0.0001). Other outcomes could not be meta-analysed due to differences in timeframe in the included studies.

CONCLUSIONS  VSE combination therapy administered in cardiopulmonary resuscitation led to improved rates of ROSC. Future trials of VSE therapy should evaluate survival to hospital discharge, neurological function and long-term survival.

Item Type: Article
DOI/Identification number: 10.11909/j.issn.1671-5411.2022.09.002
Subjects: R Medicine
Divisions: Divisions > Division of Natural Sciences > Kent and Medway Medical School
Depositing User: Gary Tse
Date Deposited: 30 Jan 2023 14:45 UTC
Last Modified: 05 Nov 2024 13:05 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/99777 (The current URI for this page, for reference purposes)

University of Kent Author Information

  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.